Nxera Pharma Co., Ltd.
SOLTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $86,900 | $116,295 | $121,803 | $159,499 |
| - Cash | $32,268 | $49,065 | $66,557 | $60,087 |
| + Debt | $67,900 | $73,973 | $29,734 | $29,271 |
| Enterprise Value | $122,532 | $141,203 | $84,980 | $128,683 |
| Revenue | $28,835 | $12,766 | $15,569 | $17,712 |
| % Growth | 125.9% | -18% | -12.1% | – |
| Gross Profit | $21,219 | $9,664 | $14,643 | $16,779 |
| % Margin | 73.6% | 75.7% | 94.1% | 94.7% |
| EBITDA | $105 | -$5,707 | $3,179 | $8,188 |
| % Margin | 0.4% | -44.7% | 20.4% | 46.2% |
| Net Income | -$4,838 | -$7,193 | $382 | $1,017 |
| % Margin | -16.8% | -56.3% | 2.5% | 5.7% |
| EPS Diluted | -53.95 | -87.17 | 4.63 | 12.4 |
| % Growth | 38.1% | -1,982.7% | -62.7% | – |
| Operating Cash Flow | -$7,718 | -$5,273 | $9,952 | $7,095 |
| Capital Expenditures | -$1,537 | -$851 | -$303 | -$201 |
| Free Cash Flow | -$9,255 | -$6,124 | $9,649 | $6,894 |